Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni with a vision of enabling regenerative medicine to become reality. Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials. For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes. Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process. Source
No articles found.
Amarantus BioSciences is a development-stage, publicly-traded biotechnology compan...
Amarantus BioSciences is a development-stage, p...
Dicerna is a biopharmaceutical company focused on the discovery and development of...
Dicerna is a biopharmaceutical company focused ...
ContraFect is a clinical-stage biotechnology company focused on discovering and de...
ContraFect is a clinical-stage biotechnology co...
We are an established, commercial-stage diagnostics company committed to reducing ...
We are an established, commercial-stage diagnos...
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting ...
Integra LifeSciences, a world leader in medical...
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focu...
Anthera Pharmaceuticals, Inc., a development st...
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...
BioCardia, Inc., headquartered in San Carlos, C...
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on ...
Organogenesis Holdings Inc. is a leading regene...
Join the National Investor Network and get the latest information with your interests in mind.